The current direction in cancer research is rational drug design, which is based on the evidence that transformed cells are characterized by alterations of genes devoted to the regulation of both cell proliferation and apoptosis. A variety of approaches have been carried out to develop new agents selective for cancer cells. Among these, antisense oligonucleotides (ASOs) are one of such class of new agents able to inhibit specifically the synthesis of a particular cancer-associated protein by binding to proteinencoding RNA, thereby preventing RNA function. In the past decade, several ASOs have been developed and tested in preclinical and clinical studies. Many have shown convincing in vitro reduction in target gene expression and promising activity against a wide variety of tumors. However, because of the multigenic alterations of tumors, the use of ASOs as single agents does not seem to be effective in the treatment of malignancies. Antisense therapy that interferes with signaling pathways involved in cell proliferation and apoptosis are particularly promising in combination with conventional anticancer treatment. An overview of the progress of ASOs used in combination therapy is provided. Oncogene (2003 Oncogene ( ) 22, 6579-6588. doi:10.1038 Keywords: antisense; molecular targets; proliferation; apoptosis; combination therapy
Antisense therapy: rationale and limitations
The use of antisense oligonucleotides (ASOs) as therapeutic agents in oncology has been proposed for longer than 10 years. ASOs are short single-stranded DNA molecules, complementary to an RNA strand, capable of specifically targeting and inhibiting the mRNA of a chosen gene. Once bound to the RNA target, its inhibition occurs through various mechanisms, including modulation of splicing and inhibition of protein translation. However, antisense-mediated inhibition of gene expression is mainly due to the recruitment of endogenous RNase H, an ubiquitous endonuclease that recognizes the mRNA-oligos duplex and cleaves the RNA strand, leaving intact the antisense, which can bind other molecules of the RNA target (Baker and Monia, 1999; Crooke, 1999; Koller et al., 2000) . Although inhibition of gene expression seems to be the predominant biological mechanism of ASOs, nonantisense effects, which may also contribute to the overall response, have been described. Nonantisense effects include potential immune stimulation by sequences such as CpG motifs or G quarter (Wooldridge et al., 1997) .
The use of ASOs for inhibition of gene expression raises several problems, including their possible degradation by nucleolytic enzymes and the difficulty of ASOs to cross cell membrane. To avoid problems resulting from sensitivity to nuclease, various modifications to the oligonucleotide backbone have been made. One of the earliest modifications brought to the ASOs chain was the replacement of one of the nonbridging oxygen atoms at each phosphorus by a methyl group, thus producing a methylphosphonate (Miller and Ts'o, 1987; Miller, 1992) . This substitution renders the ASO molecules resistant to nuclease, but unfortunately it also produces additional changes to the chemical nature of the molecule that might reduce its antisense activity. Another important backbone modification was the substitution of a sulfur atom for oxygen atoms at each phosphorus, generating a phosphorothioate (PS ASOs). This kind of substitution renders the ASO molecules negatively charged compounds, highly soluble and relatively resistant to nuclease degradation (Stec et al., 1984) . However, preclinical and clinical studies showed that PS ASOs may have nonspecific effects, either due to nonsequence specific binding or activation of nonspecific mechanisms. In fact, it has been demonstrated that PS ASOs are able to bind to heparin-binding proteins, such as bFGF, PDGF, VEGF and their receptors (Fennewald and Rando, 1995; Guvakova et al., 1995) . Under certain circumstances, PS ASOs are able to activate SP1 transcription factor and their degradation products can affect cell proliferation and differentiation (Perez et al., 1994) . PS ASOs can also enhance NK cell activity, leading to biological effects combining sequence and nonsequence specific mechanisms (Boggs et al., 1997) . Notwithstanding the existence of nonspecific interaction, PS ASOs have been successfully used in a large number of experiments designed to downregulate gene expression, and they have been and are currently used in several clinical therapeutic trials. A different class of modified oligos employed in clinical use is represented by the mixed backbone (MBO), which contains phophorothioates and segments of modified oligodeoxynucleotides or oligoribonucleotides.
In particular, the incorporation of 2 0 -O-methyloligoribonucleosides at the 5 0 and 3 0 ends of PS ASOs improves duplex affinity and also increases stability to nuclease degradation (Agrawal and Zhao, 1998) . These chemical modifications reduce toxic effects, while the antitumoral efficacy is maintained if compared to PS ASOs.
The efficacy of ASOs in inhibiting gene expression also depends on their ability to penetrate targeted cells. Considering the polyanionic features of ASOs, the difficulty of these compounds to cross the plasmamembrane passively can be understood. The uptake of ASOs occurs through active transport, which, in turn, depends on the temperature (Yakubov et al., 1989) , the structure and the concentration of oligos (Vlassov et al., 1994) . Several approaches have been explored to enhance cellular uptake and permeability of ASOs in order to increase their therapeutic efficacy, including conjugation to polycations, targeting cell surface receptors, coupling to cholesterol, encapsulation into lipid particles such as microspheres and liposomes. The use of vectors in antisense drug delivery in vivo seems to improve their biological effects.
Enthusiasm for antisense approach derives from the identification of several cancer-associated proteins, which can represent potential targets for a selective anticancer therapy with less toxic side effects than conventional chemotherapy. The preclinical development of several antisense compounds targeting cancerrelated genes has proceeded very rapidly. Figure 1 shows the key signal pathways that regulate the proliferation and the life/death decision in cancer cells. ASOs targeting cancer-related genes that interfere with both of these pathways are also shown in the figure.
This review summarizes the main promising results achieved by ASOs treatment used in combination with conventional anticancer drugs. In fact, considering the multigenic defects of human tumors, the combination of 'agents', targeting specific genes involved in tumor progression, with antineoplastic drugs represents a promising strategy for improving cancer treatment. Table 1 reports some preclinical studies of ASOs used in combination.
Antisense oligonucleotides against prosurvival-associated targets in combination therapy
Bcl-2 family
Bcl-2 and Bcl-X L proteins are inhibitors of the mitochondrial apoptosis pathway and exert their action by blocking their proapoptotic counterparts, including Bid and Bax, thereby preventing the release of cytochrome c and activation of caspases.
The bcl-2 gene has been the first negative regulator of apoptosis to be identified. It derives from 14-18 chromosomal translocation that places the bcl-2 gene under the control of immunoglobulin heavy chain, leading to its deregulated expression (Tsujimoto et al., 1985; Cleary et al., 1986) . Increased expression of Bcl-2 is found in a variety of human tumors, including lymphoma, melanoma, lung, colorectal and breast carcinomas (Reed, 1995) . Several results demonstrated that overexpression of Bcl-2 inhibits apoptosis induced by antineoplastic drugs, radiation and other damaging agents (Reed, 1994; Chao and Korsmeyer, 1998) . Based on these observations, ASOs targeting bcl-2 have been used. Several studies have been performed by using the bcl-2 ASOs produced by Genta (G3139) either as single agent or in combination with chemotherapy. G3139 is an 18-base PS ASO complementary to the first six codons of the bcl-2 mRNA. Preclinical experiments performed in B-cell lymphoma, exhibiting the t(14;18) translocation and overexpressing Bcl-2, demonstrated that the treatment with G3139 produces a significant reduction of cell growth in vitro, compared with untreated, sense-or nonsense-treated controls. On the contrary, G3139 does not produce any effect on viability either in normal fibroblasts not expressing Bcl-2 or in lymphoblastoid cells expressing Bcl-2, but without the t(14;18) translocation. The administration of G3139 in mice bearing lymphoma produces an increase in animal survival (Cotter, 1997) . The combination of antisense with a low dose of cyclophosphamide is able to cure the majority of treated animals, while chemotherapy alone does not have any significant effect on mice survival (Klasa et al., 2000) . Increased sensitivity of cytotoxic agents is also observed in other tumor histotypes such as breast, prostate, lung and gastric tumors (ZangemeisterWittke et al., 1998; Gleave et al., 1999; Chi et al., 2000) . In particular, complete tumor regression is observed when G3139 is combined with cisplatin, paclitaxel and docetaxel. Very interesting results are obtained in melanoma tumors (Jansen et al., 1998) , where Bcl-2 protein is often overexpressed and has been associated with resistance to chemotherapy (Grover and Wilson, 1996; Reed, 1999) . In particular, the treatment of some human melanoma lines in vitro with G3139 reduces Bcl-2 protein expression and induces apoptosis, while no significant effects are observed after treatment with different control oligos. The administration of G3139 in SCID mice bearing melanoma tumors produces a marked inhibition of tumor growth when compared both to untreated mice and to mice treated with control sequences. The analysis of Bcl-2 protein expression and apoptosis in tumor sections demonstrates that the efficacy of G3139 is associated with the reduction of Bcl-2 protein and with an increased number of apoptotic cells. Moreover, G3139 enhances the efficacy of dacarbazine (DTIC). In fact, while treatment with DTIC alone reduces the tumor mass by two-third if compared to untreated mice, the combination with G3139 leads to a complete regression of tumor in 10 out of 13 treated animals. The chemosensitizing effect produced by G3139 in the different tumor histotypes appears to be a bcl-2-specific antisense effect that is independent of immune stimulation, as G3139 and its immune-silent counterpart cause similar effects . On the basis of the above preclinical data, phase I/II clinical studies have been concluded (Jansen et al., 2000) . The phase III randomized trial already started in patients with advanced melanoma by using G3139 followed by DTIC. Additional multicenter trials are ongoing in multiple myeloma, chronic leukemia and lung cancer (www. genta.com).
In addition to G3139, other bcl-2 ASOs complementary to the translation initiation site of bcl-2 mRNA or targeting the bcl-2 mid-coding region were tested in a variety of preclinical models. A synergistic antitumoral effect of bcl-2 antisense therapy combined with some anticancer agents has been demonstrated in leukemia and lung cancer cells overexpressing Bcl-2 (Zangemeister- Wittke et al., 1998; Konopleva et al., 2000; Miayake et al., 2000a) .
Bcl-2 PS ASOs have also been combined with molecular therapies aimed at targeting other specific pathways. Synergistic induction of apoptosis has been observed by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways (Milella et al., 2002) or Bcl-2 and the proliferation-associated polo-like kinase I (Elez et al., 2003) . These studies provide evidence that a combination of ASOs against both proliferation and prosurvival associated targets may represent a promising antitumoral therapeutic approach. Moreover, the simultaneous suppression of different pathways significantly enhances the cytotoxicity of conventional antitumoral drugs; therefore it can be used in the treatment of resistant tumors (Liu and Gazitt, 2003; Pakunlu et al., 2003; Tanabe et al., 2003) . Recent findings obtained by independent research groups, including ours, demonstrate that Bcl-2 is also involved in the angiogenesis process through a mechanism that, at least in part, appears to be independent of its antiapoptotic function (Biroccio et al., 2000; Fernandez et al., 2001 , Iervolino et al., 2002 . Based on these observations, ASOs targeting bcl-2 might provide a therapeutic approach combining proapoptotic and antiangiogenic activity.
Alternative splicing of bcl-x pre-mRNA leads to two distinct mRNAs: the antiapoptotic bcl-x L and the proapoptotic variant bcl-x s . Recently, bcl-x PS ASOs, targeting regions shared by both splicing variants, have been used in malignant cells. All these oligos induce apoptosis in various cancer cells and sensitize tumors to chemotherapy (Lebedeva et al., 2000; Leech et al., 2000; Simoes-Wust et al., 2000) . However, since the crossspecificity for the proapoptotic bcl-x s could be undesirable, bcl-x PS ASOs designed to shift the splicing pattern of bcl-x pre-mRNA from the antiapopotic to the proapoptotic variant, or PS ASOs targeting a sequence in the bcl-x that is specific for bcl-x L , were tested. Antisense-mediated shift of bcl-x pre-mRNA splicing is effective in sensitizing cells to apoptosis and in enhancing the efficacy of standard anticancer regimens (Taylor et al., 1999; Mercatante et al., 2002) . Similarly, specific downregulation of Bcl-x L (4259) in different tumor histotypes leads to activation of apoptosis, decreases cellular proliferation rate and resistance to cytotoxic chemotherapeutic agents Simoes-Wust et al., 2000; Heere-Ress et al., 2002; Vilenchik et al., 2002) . Based on some evidences supporting the distinct biologic roles of Bcl-2 and Bcl-x L proteins in protecting cells from apoptosis, bcl-2 and bcl-X L PS ASOs have also been used in combination, even though several problems related to antisense complementarity have been observed (Miayake et al., 2000b) . To overcome this limitation, a bcl-2/bcl-x L bispecific oligonucleotide (4625), which hybridizes to a short region of high homology shared by bcl-2 and bcl-x L mRNA, was generated. These oligos simultaneously inhibit the expression of both proteins and induce apoptosis in tumor cells of different histotypes both in vitro and in vivo Gautschi et al., 2001; Olie et al., 2002; Jiang et al., 2003) . Strong synergistic interactions between oligonucleotide 4625 and anticancer drugs were observed in breast carcinoma cells (Simoes-Wust et al., 2002) and the combined inhibition of Bcl-2/Bcl-x L , epidermal growth factor receptor (EGFR) and protein kinase A (PKA) type I causes potent antitumor, apoptotic and antiangiogenic activity in breast and colon carcinomas both in vitro and in vivo (Tortora et al., 2003) .
Clusterin/Trpm-2
Clusterin, also known as testosterone-repressed prostate message-2 (TRPM-2), is a glycoprotein secreted by a number of cell types, implicated in a wide variety of physiological processes, including tissue remodeling, reproduction, lipid transport, complement regulation and apoptosis. Moreover, since clusterin expression is increased in various benign and malignant tissues undergoing apoptosis, it has been regarded as a marker for cell death. In prostate cancer, experimental and clinical studies suggest that clusterin increases after therapeutic cell death signals, such as androgen ablation or chemotherapy, and has a protective role against apoptotic cell death. Therefore, clusterin PS ASOs were designed to reduce mRNA and protein expression, thus delaying tumor progression and enhancing chemotherapy-induced apoptosis. Systemic administration of clusterin PS ASOs in mice bearing Shionogi tumors after castration leads to an earlier onset of apoptosis and to a complete tumor regression, as well as a significant delay of emergence of androgen-independent recurrent tumors compared to control treatment (Liu and Gazitt, 2003) . However, although treatment with single-agent clusterin PS ASOs has no effect on prostate, renal and urothelial tumor growth, clusterin PS ASOs synergistically enhance the effect of cytotoxic chemotherapy. In particular, combined treatment of mice bearing androgen-independent prostate tumors with clusterin PS ASOs and paclitaxel inhibits tumor growth if compared to treatment with both agents alone, indicating that clusterin PS ASOs may be useful in enhancing the effects of cytotoxic chemotherapy in hormone-refractory prostate cancer (Miayake et al., 2000c, d) . Synergistic chemosensitization and inhibition of tumor growth are observed following treatment with clusterin PS ASOs used in combination either with radiation or chemotherapy in prostate, bladder and renal cancer (Miayake et al., 2001; Zellweger et al., 2001a Zellweger et al., , 2002 . Characteristic features of apoptotic cell death are observed both in vitro and in vivo after combined treatment of PS ASOs with paclitaxel or cisplatin, but not with either agents alone.
Second-generation MBO ASOs, targeting the translation initiation site of the clusterin gene (OGX-011), are more effective than conventional PS ASOs in decreasing mRNA and protein expression, and they have a significantly longer in vivo tissue half-life with no additional side effects (Zellweger et al., 2001b) . Weekly administration of OGX-011 is equivalent to daily treatment with clusterin PS ASOs in enhancing in vivo paclitaxel efficacy, thus supporting the use of OGX-011 over PS ASOs by increasing potency and allowing longer dosing intervals in clinical trials (Zellweger et al., 2001b) . On the basis of preclinical results, the phase I clinical trial of OGX-011 started in patients with prostate cancer (www. oncogenex.ca).
Antisense oligonucleotides against proliferationassociated targets in combination therapy
Protein kinase A PKA is the primary mediator of cAMP action in mammalian cells. It is composed of two distinct isoforms, type I (PKAI) and type II (PKAII), which differ only in their regulatory subunit, RI and RII, respectively. PKAI is required for G 1 -S cell cycle transition and the transduction of mitogenic signals from different growth factors and hormones. Expression of PKAI is increased in most human cancers and its overexpression correlates with worse prognosis and decreased survival of cancer patients. These observations led to the development of various inhibitors of PKAI, including unmodified and PS ASOs that show the ability to inhibit PKAI expression specifically. PS ASOs against PKAI cause growth inhibition and differentiation of various cancer cell lines and exhibit antitumor activity in human tumor xenografts (Yokozaki et al., 1993; Cho-Chung, 1997 ). An improvement of these effects is observed with the MBO GEM 231. This oligo elicits a better in vivo pharmacokinetic and toxicological profile than PS ASOs, and displays antitumor activity in different human tumor xenografts when given orally to mice (Wang et al., 1999) .
GEM 231 is also able to synergize with different antineoplastic drugs. In particular, oral administration of GEM 231 in combination with taxol significantly prolongs the survival of colon cancer xenografted mice when compared to either of the single agents (Tortora et al., 2000a) . Moreover, it has been reported that GEM 231 sensitizes human tumors of different histotypes to irinotecan (Agrawal et al., 2002; Wang et al., 2002a) and to the topoisomerase I inhibitor hydroxycamptothecin by exerting a synergistic effect on inducing apoptosis and reducing the growth of colon carcinoma and androgen-insensitive prostate cancer cells (Cho and Cho-Chung, 2003) .
PKAI interacts with the ligand-activated EGFR and cooperates in the transduction of mitogenic signals involved in cancer pathogenesis and progression (Tortora et al., 1997) . On the basis of this molecular interaction, a therapeutic strategy based on the combined use of GEM 231 and Iressa (ZD1839, the selective inhibitor of EGFR) has been developed. Moreover, since PKAI and EGFR inhibitors have been shown to potentiate separately the efficacy of taxanes (Tortora and Ciardiello, 2000; Tortora et al., 2000a) , the antitumor efficacy of triple combination has been evaluated. The results obtained demonstrate a cooperative effect of the three agents in inhibiting the growth of xenografted tumors of different histotype and in increasing the survival of the animals. A cooperative antiapoptotic and antiangiogenic activity of the combination seems to account for the potent antitumor efficacy observed (Tortora et al., 2001) .
The demonstration of the specific PKA phosphorylation site on Bcl-2 protein and the ability of PS ASOs PKAI to induce Bcl-2 phosphorylation, cleavage of PARP, activation of caspase-3 and, finally, apoptosis led to combine PKAI and bcl-2 ASOs (Itano et al., 1996; Srivastava et al., 1998 Srivastava et al., , 1999 Yang et al., 1998; Srivastava et al., 1999) . The results show that GEM 231 and the G3139 have a marked cooperative effect on inducing apoptosis and inhibiting the growth of human ovarian, breast and colon cancer both in vitro and in vivo (Tortora et al., 2001) . More recently, the simultaneous blockade of EGFR, PKAI and bcl-2/bcl-xL proteins by Iressa, GEM 231 and 4625 PS ASOs exhibits higher antiapoptotic and antitumoral effect than either agent alone or in twin combination (Tortora et al., 2003) .
Phase I/II dose-escalation trials of GEM 231 are now ongoing in combination with taxanes (www.hybridon. com).
c-Myb
The c-myb oncogene encodes a DNA-binding transcription factor involved in the control of the G1-S transition of the cell cycle. c-Myb protein was first detected in hematopoietic cells, where it regulates cell proliferation and differentiation. c-Myb protein is overexpressed in leukemia cells, colon carcinoma, small-cell lung carcinoma, teratocarcinoma and neuroblastoma (Alitalo et al., 1984; Griffin and Baylin, 1985; Janssen et al., 1986; Thiele et al., 1987) . c-Myb is also expressed in human and murine colonic mucosa and elevated expression occurs in premalignant adenomatous polyps and carcinomas (Thompson et al., 1998) . We found that enforced expression of c-Myb in a colon tumor line causes upregulation of Bcl-x L protein, increased the tumorigenic ability and decreased the apoptotic capacity of the tumor cells (Biroccio et al., 2001a) . We also demonstrated that c-Myb overxpression is a marker of poor prognosis in colorectal cancer, frequently associated with Bcl-x L overexpression and aneuploidy. All these biological properties legitimate c-myb gene as an ideal target for antisense therapy in human neoplasia where c-Myb protein is deregulated.
It has been reported that c-myb PS ASOs inhibit the cell growth of leukemic cell lines as well as the growth of cells derived from patient biopsies in vitro and increase animal survival (Calabretta et al., 1991; Ratajczak et al., 1992) . c-myb PS ASOs were also employed as bone marrow purging agents for chronic myelogenous leukemia patients. The results demonstrate that purging of CD34 þ cells with c-myb PS ASOs decreases c-Myb and Bcr/abl expression and cytogenetic analysis shows a complete/partial response in 45% of patients (Luger et al., 2002) . Similarly, the treatment of melanoma tumors with c-myb PS ASOs inhibits the in vitro growth of cells and decreases the growth of tumors implanted in SCID mice (Hijiya et al., 1994) . In colon cancer, our group demonstrated that an 18-mer c-myb PS ASO, corresponding to the translation region of the human cmyb mRNA, inhibits in vitro cell growth. This effect is mainly due to cell cycle perturbations induced by oligos. In fact, PS ASOs treatment causes an accumulation in the G 0 /G 1 phases of the cell cycle with a relative S phase depletion. Systemic administration of c-myb PS ASOs for 7 consecutive days in nude mice bearing colon tumors causes a significant tumor weight inhibition. However, the efficacy of c-myb PS ASOs is reversible and, 4 days after tumor growth delay, the tumors' regrowth is similar to that of untreated tumors. The ability of PS ASOs in enhancing the efficacy of cytotoxic drugs has also been reported by our group. In particular, we demonstrated that the combination of cisplatin and c-myb PS ASOs produces an increased inhibition of cell proliferation, which is maintained during the growth days. Cisplatin exerts its antiproliferative activity independently of a direct effect on c-myb expression, as c-myb mRNA levels were not downregulated in cultures treated with cisplatin alone. The in vitro results were validated by the in vivo data showing a significant increase of tumor mass inhibition following the combination treatment without toxic effects (Del Bufalo et al., 1996) . The ability of c-myb PS ASOs to sensitize human colon cancer cells to cisplatin was confirmed by a study performed by Funato et al. (2001) . The authors used tumor cells resistant to cisplatin treatment and overexpressing c-Myb if compared to the sensitive parental line.
Further efforts must be focused on evaluating the antitumor efficacy of c-myb PS ASOs combined with molecules capable of blocking the expression of target genes involved in cancer progression and metastasis (Cox-2, bcl-2, bcl-x L , c-myc) and/or antitumoral drugs (Ramsay et al., 2003) .
Antisense oligonucleotides against genes involved in both proliferation and survival pathways in combination therapy c-Myc c-myc is a member of the myc gene family, which also includes N-myc, L-Myc and B-myc. The most investigated myc gene, c-myc, is a key regulator of cell growth that has been found altered by amplification or point mutation in a large subset of tumors, including leukemia, melanoma, prostate, breast and colon carcinomas (Dang, 1999) . Based on these findings, ASOs against c-myc have been studied as potential therapeutic agents. Specific c-Myc downregulation by PS ASOs reduces cell proliferation and induces terminal differentiation in leukemia cells in vitro (Holt et al., 1988; Wickstrom et al., 1988) . Simultaneously targeting c-myc and bcr-abl by antisense strategy produces a marked increase in the survival of mice bearing leukemia cells (Skorski et al., 1995 (Skorski et al., , 1996 . Moreover, the delay of tumor appearance or prevention of tumor formation was obtained in an animal model of Burkitt's lymphoma treated with c-myc PS ASOs (Huang et al., 1995; Smith and Wickstrom, 1998a, b) . c-myc antisense therapy has been used for the treatment of several other tumor histotypes. In particular, treatment with c-myc PS ASOs reduces viability and in vitro proliferation of human prostate, breast and liver cancer cells (Watson et al., 1991; Kang et al., 1996; Balaji et al., 1997; Steiner et al., 1998; Ebinuma et al., 2001) . The mechanism of growth arrest induced by c-myc PS ASOs appears to be a consequence of cyclin D1 inhibition (Carroll et al., 2002) . Tumor cell proliferation control has also been achieved by treating cells with c-myc PS ASOs in combination with different antineoplastic agents. A combination of c-myc antisense with tamoxifene in breast cancer antagonized the tamoxifene-induced increase in c-myc mRNA and protein expression (Kang et al., 1996) . Moreover, treatment with c-myc PS ASOs in combination with all-trans retinoic acid inhibits the proliferation of small-cell lung cancer, and is much more effective than both agents given alone (Akie et al., 2000) .
The use of c-myc PS ASOs as potential therapeutic agents in human melanoma treatment has been extensively investigated by our group. We demonstrated that treatment of some human melanoma lines with a 15-mer c-myc PS ASO, complementary to the translation initiation region of c-myc RNA, reduces cell proliferation and induces apoptosis by specifically inhibiting c-myc mRNA and protein expression. In vivo experiments performed in mice bearing human melanoma cells reveal that c-myc PS ASOs induce a marked inhibition of tumor growth and increase mice survival . A combination of c-myc PS ASOs and cisplatin, a drug commonly used in the treatment of melanomas, exerts a significant antiproliferative effect and activation of apoptosis greater than either agents used alone. Antitumoral effect is more effective when cisplatin is followed by c-myc PS ASOs treatment if compared to the opposite sequence. The importance of the sequence administration of the two agents has also been observed by other authors in Lewis lung carcinoma by using cisplatin or taxol followed by phosphorodiamidate morpholino oligomer (Knapp et al., 2003) . We also evaluated the efficacy of c-myc PS ASOs and cisplatin combination in vivo. Mice bearing human melanoma tumors and treated with cisplatin and c-myc PS ASOs combination show a higher inhibition of tumor growth and an increase in lifespan if compared to animals treated with either of the agents alone (Citro et al., 1998) . These results are illustrated in Figure 2 . Moreover, by using a human metastatic melanoma inherently resistant to cisplatin, we also demonstrated that the treatment with c-myc PS ASOs is able to overcome drug resistance by activating the apototic program (Leonetti et al., 1999) . Recently, we used a 16-mer c-myc PS ASO (INX-6295) encapsulated in lipid particles. The systemic administration of encapsulated INX-6295 improves the pharmacokinetics of oligo when compared to the free one, leading to a significant enhancement of tumor accumulation and distribution. Animals treated with INX-6295 exhibit a prolonged reduction of c-Myc expression, a reduced tumor growth and an increased survival. When administered in combination with cisplatin, INX-6295 produces a complete tumor regression in approximately 30% of treated mice . The efficacy of cMyc downregulation to inhibit cell proliferation and to synergize with cisplatin in melanoma cells has been subsequently observed by other authors by using psoralen-and acridine-modified ASOs (Stewart et al., 2001 (Stewart et al., , 2002 . A dose-escalation phase I clinical study in combination with cisplatin has been completed on patients with solid tumors and lymphomas (Gelmon et al., 2001) . The results demonstrated that c-myc PS ASOs are well tolerated and do not increase the toxicity of cisplatin. Partial responses have also been observed. Further clinical studies are mandatory to establish the efficacy of this antitumoral strategy.
Notwithstanding the well-established involvement of c-Myc protein in cisplatin sensitivity, the susceptibility to other antineoplastic drugs is still controversial. In fact, modulation of c-Myc expression has been reported to enhance tumor cell sensitivity and to induce resistance to antineoplastic agents. These controversial results seem to be dependent, at least in part, on the mechanism of drug action. In fact, by using stable transfected melanoma clones, we demonstrated that c-Myc downregulation increases the sensitivity to cisplatin, without affecting the response to adriamycin and camptothecin (Biroccio et al., 2001b) . Moreover, in human p53-mutant small-cell lung cancer cells, we found that inhibition of c-Myc expression by PS ASOs almost abolishes the apoptotic response induced by doxorubicin (Supino et al., 2001) . These results suggest the use of c-myc PS ASOs in combination with some kinds of drugs rather than others.
In our laboratory, we performed experiments aimed at identifying other molecular targets involved in melanoma tumorigenicity and drug resistance, in order to improve the treatment of resistant tumors. Macroarray analysis, performed to compare the gene expression profile of control and c-Myc low-expressing cells, reveals that downregulation of c-Myc produces striking changes in the expression of glutathione (GSH)-related metabolism genes, where the expressions of g-glutamylcysteine synthetase and GSSG reductase are found to be significantly reduced. This imbalance of GSH is responsible for the activation of apoptosis induced by c-Myc downregulation (Biroccio et al., 2002a) . By using the same experimental model, we also demonstrated that telomerase dysfunction caused by c-Myc downregulation is involved in the c-Myc-dependent tumorigenicity and drug sensitivity (Biroccio et al., 2002b (Biroccio et al., , 2003 . These results suggest the use of c-myc PS ASOs in combination with GSH depletors and/or agents targeting telomerase function in the treatment of melanoma tumors.
MDM2
mdm2 is an oncogene that has been found overexpressed in a variety of human malignancies. It works as a negative regulator of the p53 tumor suppressor, which interferes with the control of cell proliferation and apoptosis. MDM2 not only interacts with p53 but also with p14ARF, which antagonizes its function as a suppressor of p53, Rb and E2F, thus contributing to the development and maintenance of malignant phenotype. For all these reasons, MDM2 is considered to be a potentially relevant target for cancer therapy. PS ASOs against mdm2 mRNA have been used in a wide panel of tumor lines both in vitro and in vivo. Moreover, a novel class of MBO containing centrally modified or end-modified nucleosides has been synthesized, to overcome some limitations displayed by PS ASOs in vivo and tested in prostate, colon and breast carcinomas (Tortora et al., 2000b; Wang et al., 2001 Wang et al., , 2002b Wang et al., , 2003 . Inhibition of MDM2 expression induces both p53 and p21/WAF1 expression, accumulation and growth inhibition. mdm2 MBOs also show a cooperative growth-inhibitory effect with several classes of cytotoxic drugs with different mechanism of action. mdm2 MBOs also induce apoptosis and markedly enhance the apoptotic activity of antineoplastic drugs. Moreover, mdm2 MBOs show an antitumoral activity in vivo, in terms of inhibition of tumor growth, tumor growth delay and increase of mice survival. In vivo administration of mdm2 MBOs leads to a synergistically or additive therapeutic effect of the cancer chemotherapeutic agents irotecan, 5-fluorouracil, paclitaxel, cisplatin and doxorubicin. Inhibition of tumor growth, induction of apoptosis, and the chemosensitizing effect after treatment with mdm2 MBOs occurs both in wild-type and mutant p53 tumors (Wang et al., 2001 (Wang et al., , 2002b . These results suggest that mdm2 MBOs have a role in cancer development and progression through both p53-dependent and -independent mechanisms.
Conclusions and perspectives
The preclinical development of several ASOs targeting cancer-relevant genes has proceeded very rapidly. Many ASOs have shown convincing in vitro reduction in target gene expression and promising activity against a variety of human malignancies. However, considering the multitude of molecular entities and signaling pathways that regulate the proliferation and the life/death decision in cancer cells, inhibition of a single target gene is not sufficient to suppress tumor growth. Several evidences from cell cultures and animal models established that Antisense in combination therapy A Biroccio et al targeted inhibition of genes involved in controlling cell proliferation and apoptosis combined with anticancer treatments is a promising approach for cancer therapy. Moreover, clinical trials showed that ASOs are well tolerated and do not increase the toxicity of conventional treatments. However, the following stages of clinical studies demonstrated that even thought the antisense treatment resulted effective in improving the response of patients to conventional therapies, most antisense/drug combined strategy did not lead to a significant increase of survival. This can be due both to limitations in our understanding of the molecular basis of cancer and, mostly, to inadequate clinical settings and lack of appropriate selection of patients based on a deep knowledge of the function of the chosen target. Recent technological advances in both genomic and proteomic wide views of tumor biology might in the future help address more specific and adequate therapies.
